Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug-Receptor Bonds01:25

Drug-Receptor Bonds

3.1K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
3.1K
Enzyme Inhibition01:30

Enzyme Inhibition

79.0K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
79.0K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

7.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

3.2K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
3.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

The repressor Capicua is a barrier to lung tumor development driven by Kras/Trp53 mutations.

EMBO molecular medicine·2025
Same author

The rapidly growing landscape of RAS inhibitors: from selective allele blockade to broad inhibition strategies.

Molecular oncology·2025
Same author

Systemic <i>Kras</i> ablation disrupts myeloid cell homeostasis in adult mice.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

Active R-RAS2/TC21 prevents cell cycle arrest and morphological alterations in mouse embryonic fibroblasts lacking RAS proteins.

Oncogene·2025

Related Experiment Video

Updated: Aug 21, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K

KRAS inhibitors: going noncovalent.

Matthias Drosten1, Mariano Barbacid2

  • 1Molecular Mechanisms of Cancer Program, Centro de Investigación del Cáncer (CIC) and Instituto de Biología Molecular y Celular del Cáncer (IBMCC), CSIC-USAL, Salamanca, Spain.

Molecular Oncology
|November 16, 2022
PubMed
Summary

Researchers developed MRTX1133, a novel noncovalent inhibitor targeting the KRAS G12D mutation common in pancreatic and colorectal cancers. This drug demonstrated significant antitumor effects in preclinical models, offering new therapeutic possibilities.

Keywords:
KRASG12Dcolorectal cancercombination therapiesnoncovalent bindingpancreatic ductal adenocarcinoma

More Related Videos

Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay
06:17

Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay

Published on: February 28, 2025

653
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

542

Related Experiment Videos

Last Updated: Aug 21, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K
Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay
06:17

Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay

Published on: February 28, 2025

653
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

542

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • KRAS G12D mutations are prevalent in pancreatic and colorectal cancers, driving tumor growth.
  • Targeting KRAS mutations is a key strategy in cancer therapy.

Purpose of the Study:

  • To identify and validate a novel, potent, selective, and noncovalent inhibitor for KRAS G12D.
  • To evaluate the antitumor activity of MRTX1133 in preclinical cancer models.

Main Methods:

  • Structure-based drug design informed by KRAS G12C inhibitor adagrasib.
  • In vitro and in vivo testing of MRTX1133 in pancreatic and colorectal cancer models.
  • Combination studies with cetuximab (anti-EGFR) and BYL-719 (PI3Kα inhibitor).

Main Results:

  • Identification and validation of MRTX1133, a potent and selective noncovalent KRAS G12D inhibitor.
  • MRTX1133 inhibited both inactive and active states of KRAS G12D.
  • Significant antitumor activity observed in preclinical models, enhanced by combination therapies.

Conclusions:

  • MRTX1133 represents a promising therapeutic candidate for KRAS G12D-driven cancers.
  • Combination strategies involving MRTX1133 may enhance treatment efficacy.